国产成人嫩模一区二区|超级黄色网页|兔子先生tz|麻豆文化传媒网站官网污|在线播放欧美日韩精品|爱豆影视传媒免费下载|蜜桃影像传媒av剧情|麻豆文化传媒APP最新iOS|陈可心倩女幽魂爱豆传媒|91国视频产,国产传媒播放,想看三级片,网红吃瓜黑料爆料网反差

undefined

SHEN Ying

Professor

E-mail: [email protected]

Tel: 021-63846590-776976

Research Field: Anti-tumor pharmacology; Metabolism reprogramming during drug resistance and tumor metastasis in lung cancer; Discovery and development of novel inhibitors targeting key enzymes in cancer cell metabolism.

Personal Introduction

  • Ying Shen, Ph.D., Professor

  • Principle Investigator (PI) of Anti-tumor pharmacology lab

  • Vice Director, Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai

  • Professor Ying Shen graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and finished her postdoctoral training at University of California San Diego (UCSD). She has worked at Shanghai Jiao Tong University School of Medicine since 2009. Her research work focuses on metabolism reprogramming and related molecular mechanisms during targeted drug resistance and tumor metastasis in lung cancer, discovery and development of novel inhibitors targeting key enzymes in cancer cell metabolism. Relevant works have been published in high-rank SCI journals such as Cell Metab, Drug Resist Updat, Cancer Res, Sci Transl Med and have granted five patents. The cooperation potent have signed a transformation cooperation agreement.

Selected publications

  1. Ke Huang#, Qian Liang#, Ye Zhou#, Lu-lu Jiang, Wei-ming Gu, Ming-yu Luo, Ya-bin Tang, Yang Wang, Wei Lu, Min Huang, Sheng-zhe Zhang, Guang-lei Zhuang, Qing Dai, Qian-cheng Shen, Jian Zhang, Hui-min Lei, Liang Zhu, De-yong Ye, Hong-zhuan Chen*, Lu Zhou, Ying Shen*(最后通訊). A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small cell lung cancer. Cell Metabolism, 2019 Dec 3, 30(6):1107-1119.e8 (IF2019: 21.567)

  2. Qian Liang#, Miao-miao Gong#, Jing-hua Zou#, Ming-yu Luo, Lu-lu Jiang, Cheng Wang, Ningxiang Shen, Mo-cong Zhang, Lu Xu, Hui-min Lei, Ke-ren Zhang, Rui Zhang, Guang-lei Zhuang, Liang Zhu, Hong-zhuan Chen*, Lu Zhou*, Ying Shen*(最后通訊). A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma, Drug Resistance Updates, 2023 May;68:100957. (IF2023: 15.8)

  3. Ming-yu Luo#, Ye Zhou#, Wei-ming Gu#, Cheng Wang, Ning-xiang Shen, Jiang-kai Dong, Hui-min Lei, Ya-bin Tang, Qian Liang, Jing-hua Zou, Lu Xu, Pengfei Ma, Guanglei Zhuang, Ling Bi, Ling Xu, Liang Zhu, Hong-zhuan Chen, Ying Shen(唯一通訊). Metabolic and non-metabolic functions of PSAT1 coordinate signaling cascades to confer EGFR-inhibitor resistance and drive progression in lung adenocarcinoma. Cancer Research, 2022 Oct 1;82(19):3516–31. (IF2022: 11.2) 封面文章

  4. Ke-ren Zhang#, Yu-fei Zhang#, Hui-min Lei#, Ya-bin Tang#, Chun-shuang Ma, Qian-ming Lv, Shiyi Wang, Li-ming Lu, Ying Shen*(共同通訊), Hong-zhuan Chen*, Liang Zhu*. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Science Translational Medicine, 2021 Oct 6, 13(614): eabg6428. (IF2021: 19.315)

  5. Ning-xiang Shen#, Ming-yu Luo#, Wei-ming Gu#, Miaomiao Gong, Hui-min Lei, Ling Bi, Cheng Wang, Mo-cong Zhang, Guanglei Zhuang, Lu Xu, Liang Zhu, Hong-zhuan Chen, Ying Shen(唯一通訊). GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma. Oncogene, 2024 Jul 5; 43:2504–16. (IF2023: 6.9)

  6. Cheng Wang#, Minghao Zhang#, Shunyao Li#, Miaomiao Gong#,*, Ming-yu Luo, Mo-cong Zhang, Jing-Hua Zou, Ningxiang Shen, Lu Xu, Hui-min Lei, Ling Bi, Liang Zhu, Zhengting Wang, Hong-zhuan Chen*, Lu Zhou*, Ying Shen*(最后通訊). A Phosphoglycerate Mutase 1 Allosteric Inhibitor Restrains TAM-mediated colon cancer progression. Acta Pharmaceutica Sinica B, 2024. https://doi.org/10.1016/j.apsb.2024.09.007. (IF2023: 14.7)

  7. Qian Liang#, Wei-ming Gu#, Ke Huang#, Ming-yu Luo, Jing-hua Zou, Guang-lei Zhuang, Hui-min Lei, Hong-zhuan Chen, Liang Zhu*, Lu Zhou*, Ying Shen*(最后通訊). HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2021 Jan, 42(1):115-119. (IF2021: 7.169)

Lab Members

Name Title Email
Lu Xu Associate Professor [email protected]
Miaomiao Gong Associate Professor [email protected]